Search CommunityWalk:


GlycoMimetics, Inc.

401 Professional Drive, Suite 250
Gaithersburg, MD, USA

Category: Pharmaceutical

Used in the following map:

Maryland Biotech Industry Map

GlycoMimetics, Inc. is a biopharmaceutical company, engaged in developing small molecule drugs targeting areas of unmet clinical needs with a focus on rare diseases.

GlycoMimetics' pipeline is focused on applying specialized platform technology to the development of drugs to treat rare or orphan diseases. The drug candidates are first-in-class proprietary small molecules. It has designed and synthesized a novel class of patented anti-inflammatory compounds that are selectin antagonists.

GlycoMimetics uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The company has designed and synthesized a family of compounds that are antagonists of both E-selectin and CXCR4. Its GMI-1070 is a synthetic glycomimetic molecule, which was rationally designed to inhibit all three selectin types (a pan-selectin inhibitor). The company has also developed a proprietary, small molecular weight compound known as GMI-1051 for the treatment or prevention of infections caused by Pseudomonas aeruginosa.

GlycoMimetics' investors include: New Enterprise Associates, Genzyme Ventures, Alliance Technology Ventures, Anthem Capital Management, The Novartis Venture Fund, PTV Sciences, L.P and Maryland Department of Business and Economic Development. The company's partners include: National Institutes of Health, The National Heart, Lung, and Blood Institute and The U.S. Department of Health and Human Services.